Art. 3 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2022cited 127×
1.

No medicinal product appearing in the Annex may be placed on the market within the Union unless a marketing authorisation has been granted by the Union in accordance with the provisions of this Regulation.

2.

Any medicinal product not appearing in Annex I may be granted a marketing authorisation by the Union in accordance with this Regulation, if:

(a)

the medicinal product contains an active substance which, on 20 May 2004, was not authorised in the Union; or

(b)

the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorisation in accordance with this Regulation is in the interest of patients' health at Union level.

3.

A generic medicinal product of a reference medicinal product authorised by the Union may be authorised by the competent authorities of the Member States in accordance with Directive 2001/83/EC under the following conditions:

(a)

the application for authorisation is submitted in accordance with Article 10 of Directive 2001/83/EC;

(b)

the summary of the product characteristics is in all relevant respects consistent with that of the medicinal product authorised by the Union except for those parts of the summary of product characteristics referring to indications or dosage forms which were still covered by patent law at the time when the generic medicine was marketed; and

(c)

the generic medicinal product is authorised under the same name in all the Member States where the application has been made. For the purposes of this provision, all the linguistic versions of the INN (international non-proprietary name) shall be considered to be the same name.

4.

After the competent committee of the Agency has been consulted, the Commission may adapt the Annex to technical and scientific progress and may adopt any necessary amendments without extending the scope of the centralised procedure.

Those measures, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 87(2a).

The 10 that are cited most themselves, of 127.

  • Directive (EU) 2001/835aLaw

    … на лекарствен продукт, спадащ към категориите, посочени в член 3, параграфи 1 и 2 от Регламент (ЕО) № 726/2004, ако са изпълнени всички …

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    On 21 July 2011, the Committee for Medicinal Products for Human Use (‘the CHMP’), established by Article 5(1) of Regulation No 726/2004, considered that Biogen Idec’s product, containing DMF, was eligible for submission of an …

    5 May 2021 · 62018TJ0611

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    On 27 November 2017, Polpharma submitted a request to the EMA for confirmation that it was eligible to submit a marketing authorisation application under the centralised procedure in accordance with Article 3(3) of Regulation No 726/2004 …

    16 Mar 2023 · 62021CJ0438

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…31Law

    Без да се засяга член 3, параграф 2 от Регламент (ЕО) № 726/2004, заявлението за издаване на разрешително за употреба и търгуване на …

  • Regulation (EU) 2019/5Lawamends

  • Gesetz über den Verkehr mit Arzneimitteln21254852bLaw

    … für sie die Europäische Gemeinschaft oder die Europäische Union eine Genehmigung für das Inverkehrbringen nach Artikel 3 Absatz 1 oder 2 der Verordnung (EG) Nr. 726/2004 erteilt hat. Satz 1 gilt auch in Verbindung mit der Verordnung …

  • Judgment of the Court (Fourth Chamber), 11 April 2013. Novartis Pharma GmbH v Apozyt GmbH.Decisioninterprets

    This request for a preliminary ruling concerns the interpretation of Article 3(1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and …

    11 Apr 2013 · 62011CJ0535

  • Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision

    On 27 November 2017, the company Pharmaceutical Works Polpharma S.A. submitted a request to the EMA seeking confirmation that it was eligible to submit an application for marketing authorisation under the centralised procedure in …

    4 Aug 2022 · 62022TO0278

  • Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision

    On 27 November 2017, the company Pharmaceutical Works Polpharma S.A. submitted a request to the EMA seeking confirmation that it was eligible to submit an application for marketing authorisation under the centralised procedure in …

    4 Aug 2022 · 62022TO0269

  • Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision

    On 27 November 2017, the company Pharmaceutical Works Polpharma S.A. submitted a request to the EMA seeking confirmation that it was eligible to submit an application for marketing authorisation under the centralised procedure in …

    4 Aug 2022 · 62022TO0279